Drug intelligence / Profile preview

OX-SR

Development stage: Preclinical
Modality: Peptides
Administration: Injection

Overview

OX-SR is a research compound identified as an oxyntomodulin analogue. It is being developed for the treatment of obesity and associated complications. Its mechanism of action involves acting as a dual agonist for both the glucagon receptor and the glucagon-like peptide 1 (GLP-1) receptor. This dual agonism leads to a reduction in appetite, an increase in energy expenditure, and improvements in overall metabolic profile and glucose homeostasis.

Targets

GCGR (Glucagon receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on OX-SR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OX-SR.

Explore the full profile